{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:18:42Z","timestamp":1793837922520,"version":"4.6.1"},"reference-count":167,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T00:00:00Z","timestamp":1732406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100023656","name":"University of California, Los Angeles - International Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023656","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"University of California Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ymthe.2024.11.035","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T01:53:34Z","timestamp":1732586014000},"page":"2368-2390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Managing allorejection in off-the-shelf CAR-engineered cell therapies"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-300X","authenticated-orcid":false,"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyue","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibai","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.11.035_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging Cellular Therapies for Cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The Principles of Engineering Immune Cells to Treat Cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.11.035_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.11.035_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2024.11.035_bib6","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.035_bib7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.it.2021.01.004","article-title":"Taking T-Cell Oncotherapy Off-the-Shelf","volume":"42","author":"Mo","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib8","article-title":"Allogeneic CAR Cell Therapy-More Than a Pipe Dream","volume":"11","author":"Caldwell","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.11.035_bib10","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.ymthe.2024.04.005","article-title":"Engineering Allorejection-Resistant CAR-NKT Cells from Hematopoietic Stem Cells for Off-The-Shelf Cancer Immunotherapy","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.035_bib11","first-page":"1","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","author":"Li","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib12","article-title":"Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy","volume":"2","author":"Li","year":"2021","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.ymthe.2024.11.035_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-cancerbio-062822-023316","article-title":"Allogeneic CAR T Cell Therapy for Cancer","volume":"8","author":"Sasu","year":"2024","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.11.035_bib15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.stem.2023.02.009","article-title":"Advancing cell-based cancer immunotherapy through stem cell engineering","volume":"30","author":"Li","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.11.035_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","article-title":"Current Concepts and Advances in Graft-Versus-Host Disease Immunology","volume":"39","author":"Hill","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat8410","article-title":"Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells","volume":"10","author":"Tugues","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044084","article-title":"Graft-versus-Host Disease Modulation by Innate T Cells","volume":"24","author":"Fang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.11.035_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123497","article-title":"Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.11.035_bib20","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2024.11.035_bib21","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.11.035_bib22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3324\/haematol.2019.233882","article-title":"Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing \u03b1\u03b2 T cell-depleted haploidentical hematopoietic stem cell transplantation","volume":"106","author":"Wiebking","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2024.11.035_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.11.035_bib24","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-Engineered Universal CD19\/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed\/Refractory B-cell Acute Lymphoblastic Leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.035_bib25","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1182\/blood-2021-149712","article-title":"Allogeneic NKT Cells Expressing a CD19-Specific CAR in Patients with Relapsed or Refractory B-Cell Malignancies: An Interim Analysis","volume":"138","author":"Ramos","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.11.035_bib27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/sctm.20-0459","article-title":"Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions","volume":"10","author":"Arias","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib28","article-title":"From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies","volume":"11","author":"Lu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","article-title":"Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer","volume":"25","author":"Zhu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.11.035_bib30","article-title":"Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy","volume":"10","author":"Chen","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00467-008-1020-x","article-title":"Mechanism of cellular rejection in transplantation","volume":"25","author":"Ingulli","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40472-016-0115-8","article-title":"What Is Direct Allorecognition?","volume":"3","author":"Boardman","year":"2016","journal-title":"Curr. Transpl. Rep."},{"key":"10.1016\/j.ymthe.2024.11.035_bib33","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nri2200","article-title":"Specificity of T-cell alloreactivity","volume":"7","author":"Felix","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/TP.0000000000004420","article-title":"Pathways of Antigen Recognition by T Cells in Allograft Rejection","volume":"107","author":"Carnel","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.ymthe.2024.11.035_bib35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib36","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","article-title":"HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A","volume":"95","author":"Lee","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.11.035_bib37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41577-019-0200-1","article-title":"Engineering universal cells that evade immune detection","volume":"19","author":"Lanza","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1199145","article-title":"Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy","volume":"14","author":"Lv","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2023.04.017","article-title":"Presidential Symposium and Presentation of Top Abstracts","volume":"31","author":"Megan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.035_bib40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/tri.13549","article-title":"B cells in transplant tolerance and rejection: friends or foes?","volume":"33","author":"Schmitz","year":"2020","journal-title":"Transpl. Int."},{"key":"10.1016\/j.ymthe.2024.11.035_bib41","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/ajt.15323","article-title":"Outstanding questions in transplantation: B cells, alloantibodies, and humoral rejection","volume":"19","author":"Chong","year":"2019","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2024.11.035_bib42","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1111\/j.1600-6143.2010.03223.x","article-title":"B cells help alloreactive T cells differentiate into memory T cells","volume":"10","author":"Ng","year":"2010","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2024.11.035_bib43","article-title":"iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer","volume":"4","author":"Furukawa","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(00)00311-2","article-title":"Whole blood assay for assessment of the mixed lymphocyte reaction","volume":"247","author":"Bromelow","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ymthe.2024.11.035_bib45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-023-03586-1","article-title":"Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2024.11.035_bib46","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fmed.2020.00340","article-title":"Pre-existing Alloreactive T and B Cells and Their Possible Relevance for Pre-transplant Risk Estimation in Kidney Transplant Recipients","volume":"7","author":"Karahan","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib47","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1111\/ajt.12285","article-title":"Cross-validation of IFN-\u03b3 Elispot assay for measuring alloreactive memory\/effector T cell responses in renal transplant recipients","volume":"13","author":"Bestard","year":"2013","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2024.11.035_bib48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nec.2009.09.004","article-title":"Monitoring immune responses after glioma vaccine immunotherapy","volume":"21","author":"Jian","year":"2010","journal-title":"Neurosurg. Clin. N. Am."},{"key":"10.1016\/j.ymthe.2024.11.035_bib49","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-032712-095921","article-title":"Human hemato-lymphoid system mice: current use and future potential for medicine","volume":"31","author":"Rongvaux","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib50","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/ckj\/sfx050","article-title":"Complement-dependent cytotoxicity and Luminex technology for human leucocyte antigen antibody detection in kidney transplant candidates exposed to different sensitizing events","volume":"10","author":"Katalini\u0107","year":"2017","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymthe.2024.11.035_bib51","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class i expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8873383","article-title":"HLA DR Genome Editing with TALENs in Human iPSCs Produced Immune-Tolerant Dendritic Cells","volume":"2021","author":"Kwon","year":"2021","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.ymthe.2024.11.035_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s43042-021-00155-y","article-title":"HLA-A gene knockout using CRISPR\/Cas9 system toward overcoming transplantation concerns","volume":"22","author":"Amiri","year":"2021","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"10.1016\/j.ymthe.2024.11.035_bib54","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/7651_2021_352","article-title":"CRISPR\/Cas9 Ribonucleoprotein Complex-Mediated Efficient B2M Knockout in Human Induced Pluripotent Stem Cells (iPSCs)","volume":"2454","author":"Thongsin","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib55","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010239","article-title":"Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy","volume":"7","author":"Mattapally","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ymthe.2024.11.035_bib56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib57","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib58","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.11.035_bib59","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","article-title":"Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells","volume":"5","author":"Wang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2024.11.035_bib60","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1073\/pnas.1902566116","article-title":"Generation of hypoimmunogenic human pluripotent stem cells","volume":"116","author":"Han","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.11.035_bib61","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41587-022-01540-7","article-title":"Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression","volume":"41","author":"Gravina","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0352-x","article-title":"Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering","volume":"51","author":"Jang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.omtm.2022.05.010","article-title":"Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application","volume":"26","author":"Kitano","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.11.035_bib64","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ymthe.2024.11.035_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-022-00104-y","article-title":"Nanodelivery of nucleic acids","volume":"2","author":"Mendes","year":"2022","journal-title":"Nat. Rev. Methods Primers"},{"key":"10.1016\/j.ymthe.2024.11.035_bib66","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.11.035_bib67","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib68","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2021-146038","article-title":"ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma Comparable to Autologous CAR T","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib69","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2021-146045","article-title":"ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing","volume":"138","author":"Lekakis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib70","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib71","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib72","doi-asserted-by":"crossref","first-page":"10303","DOI":"10.1182\/blood-2022-166432","article-title":"CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study","volume":"140","author":"McGuirk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib73","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex Genome-Edited T-cell Manufacturing Platform for \u201cOff-the-Shelf\u201d Adoptive T-cell Immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.035_bib74","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2023-182430","article-title":"Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"142","author":"Dholaria","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib75","doi-asserted-by":"crossref","first-page":"e1789302","DOI":"10.1097\/01.HS9.0000968336.17893.02","article-title":"P356: Phase 1\/2 Dose-Escalation Study of Anti-CD7 Allogenic CAR-T Cell in Relapsed or Refractory(R\/R) T-Cell Acute Lymphoblastic Leukemia\/Lymphoblastic Lymphoma(T-ALL\/LBL)","volume":"7","author":"Ghobadi","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.ymthe.2024.11.035_bib76","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1182\/blood-2021-153150","article-title":"Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies","volume":"138","author":"Leedom","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2024.11.035_bib78","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib79","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1182\/blood-2023-187252","article-title":"Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R\/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib80","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.11.035_bib81","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamaoncol.2024.0473","article-title":"Allogeneic CD19\/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia","volume":"10","author":"Phely","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib82","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2024.11.035_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ymthe.2024.11.035_bib84","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","article-title":"Long Terminal Repeat CRISPR-CAR-Coupled \u201cUniversal\u201d T Cells Mediate Potent Anti-leukemic Effects","volume":"26","author":"Georgiadis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.035_bib85","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood.2019001212","article-title":"Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR","volume":"134","author":"Dehn","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib86","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stemcr.2023.12.003","article-title":"Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers","volume":"19","author":"Pizzato","year":"2024","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.ymthe.2024.11.035_bib87","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/emmm.201201235","article-title":"Haematopoietic stem cell survival and transplantation efficacy is limited by the BH3-only proteins Bim and Bmf","volume":"5","author":"Labi","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib88","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1084\/jem.20161721","article-title":"Transient apoptosis inhibition in donor stem cells improves hematopoietic stem cell transplantation","volume":"214","author":"Kollek","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib89","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib90","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.embor.7400640","article-title":"Inhibition of apoptosis by survivin improves transplantation of pancreatic islets for treatment of diabetes in mice","volume":"7","author":"Dohi","year":"2006","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ymthe.2024.11.035_bib91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/stem.2727","article-title":"Survivin Is Required for Mouse and Human Bone Marrow Mesenchymal Stromal Cell Function","volume":"36","author":"Singh","year":"2018","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2024.11.035_bib92","article-title":"Antiapoptotic Molecule Survivin in Transplantation: Helpful or Harmful?","volume":"2018","author":"Assadiasl","year":"2018","journal-title":"J. Trans."},{"key":"10.1016\/j.ymthe.2024.11.035_bib93","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","article-title":"3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.11.035_bib94","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrc2804","article-title":"Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer","volume":"10","author":"Jenq","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2024.11.035_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1127704","article-title":"Immunomodulation-a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system","volume":"14","author":"Strzelec","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697854","article-title":"Regulatory T Cells in GVHD Therapy","volume":"12","author":"Guo","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib97","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib98","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbmt.2018.11.020","article-title":"Effects of Low-Dose Glucocorticoid Prophylaxis on Chronic Graft-versus-Host Disease and Graft-versus-Host Disease\u2013Free, Relapse-Free Survival after Haploidentical Transplantation: Long-Term Follow-Up of a Controlled, Randomized Open-Label Trial","volume":"25","author":"Chang","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2024.11.035_bib99","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/601953","article-title":"Steroid-Refractory Acute GVHD: Predictors and Outcomes","volume":"2011","author":"Westin","year":"2011","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib100","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib101","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147683","article-title":"Calcineurin inhibitors suppress acute graft-versus-host disease via NFAT-independent inhibition of T cell receptor signaling","volume":"131","author":"Otsuka","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.11.035_bib102","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin Inhibitors: 40 Years Later, Can\u2019t Live Without","volume":"191","author":"Azzi","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib103","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1001\/jamaoncol.2019.2525","article-title":"Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?","volume":"5","author":"Unni","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib104","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1038\/s41467-024-47965-3","article-title":"Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma","volume":"15","author":"Joo","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.11.035_bib105","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1200\/JCO.2008.17.7279","article-title":"Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning","volume":"26","author":"Armand","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib106","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/14712598.7.1.137","article-title":"The role of basiliximab induction therapy in organ transplantation","volume":"7","author":"Ramirez","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.035_bib107","doi-asserted-by":"crossref","first-page":"27059","DOI":"10.1074\/jbc.M113.491530","article-title":"Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor \u03b1-associated diseases from a molecular view","volume":"288","author":"Hu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2024.11.035_bib108","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","article-title":"Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond","volume":"2007","author":"Bello","year":"2007","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ymthe.2024.11.035_bib109","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.immuni.2011.03.029","article-title":"A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity","volume":"35","author":"Haribhai","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2024.11.035_bib110","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3904\/kjim.2016.319","article-title":"Third-party regulatory T cells prevent murine acute graft-versus-host disease","volume":"33","author":"Lim","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib111","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib112","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/bloodadvances.2020003219","article-title":"First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings","volume":"5","author":"MacMillan","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.11.035_bib113","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"T(reg) cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib114","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm915","article-title":"CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib115","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI17702","article-title":"Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia","volume":"112","author":"Trenado","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.11.035_bib116","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/1078-0432.CCR-18-1211","article-title":"Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts","volume":"25","author":"Suryadevara","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.035_bib117","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41571-021-00485-1","article-title":"Will allogeneic CAR T cells for CD19(+) malignancies take autologous CAR T cells \u201coff the shelf\u201d?","volume":"18","author":"DiNofia","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib118","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib119","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.035_bib120","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1016\/j.ymthe.2022.06.006","article-title":"Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy","volume":"30","author":"Tipanee","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.035_bib121","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.11.035_bib122","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib123","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib124","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2024.11.035_bib125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.11.035_bib126","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib127","article-title":"Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design","volume":"26","author":"Li","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2024.11.035_bib128","article-title":"Tumor-Localized Administration of \u03b1-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors","volume":"23","author":"Li","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.11.035_bib129","article-title":"Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers","volume":"25","author":"Li","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2024.11.035_bib130","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.4049\/jimmunol.178.10.6242","article-title":"Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation","volume":"178","author":"Pillai","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib131","doi-asserted-by":"crossref","first-page":"e1470735","DOI":"10.1080\/2162402X.2018.1470735","article-title":"Human CD4- invariant NKT lymphocytes regulate graft versus host disease","volume":"7","author":"Coman","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2024.11.035_bib132","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib133","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.035_bib134","article-title":"Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers","author":"Steffin","year":"2024","journal-title":"Res. Sq."},{"key":"10.1016\/j.ymthe.2024.11.035_bib135","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1016\/j.clml.2023.02.003","article-title":"A Phase I Trial of Allogeneic \u03b3\u03b4 T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia","volume":"23","author":"Vydra","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ymthe.2024.11.035_bib136","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1016\/j.bbmt.2019.12.379","article-title":"Allogeneic Viral Specific T Cells Are Safe and Can be Efficient in the Treatment of Infections in Solid Organ Transplant Recipients","volume":"26","author":"Nelson","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2024.11.035_bib137","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u201coff the shelf\u201d adoptive therapy of refractory infections","volume":"51","author":"O\u2019Reilly","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.ymthe.2024.11.035_bib138","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.11.035_bib139","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.stemcr.2015.07.011","article-title":"A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy","volume":"5","author":"Ando","year":"2015","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.ymthe.2024.11.035_bib140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.stem.2012.07.014","article-title":"Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types","volume":"11","author":"Taylor","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.11.035_bib141","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.stem.2022.06.014","article-title":"EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity","volume":"29","author":"Jing","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.11.035_bib142","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2022016205","article-title":"Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies","volume":"141","author":"Cichocki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.11.035_bib143","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-023-00929-0","article-title":"Bendamustine vs. fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma","volume":"13","author":"Sidana","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2024.11.035_bib144","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.11.035_bib145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrneurol.2011.57","article-title":"Benefits of alemtuzumab in MS","volume":"7","author":"Wood","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib146","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib147","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1038\/s41467-023-44176-0","article-title":"Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.11.035_bib148","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/mt.2015.104","article-title":"A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy","volume":"23","author":"Valton","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.035_bib149","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065519","article-title":"Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy","volume":"8","author":"Jonnalagadda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.11.035_bib150","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/mt.2011.179","article-title":"Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination","volume":"19","author":"Huye","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.035_bib151","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymthe.2020.09.011","article-title":"CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients","volume":"29","author":"Amini","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.035_bib152","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable Manufacturing of CAR T cells for Cancer Immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ymthe.2024.11.035_bib153","article-title":"Cell therapy products are revolutionizing multiple therapeutic areas; to maintain this pace of innovation, manufacturing solutions must adapt","volume":"20","author":"Abraham","year":"2021","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2024.11.035_bib154","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.seminhematol.2020.07.005","article-title":"Improving CAR T cell therapy by optimizing critical quality attributes","volume":"57","author":"Reddy","year":"2020","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1388475","article-title":"Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review","volume":"14","author":"Moradi","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib156","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1433432","article-title":"\u201cOff-The-Shelf\u201d allogeneic chimeric antigen receptor T-cell therapy for B-cell malignancies: current clinical evidence and challenges","volume":"14","author":"Mohty","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib157","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bej.2018.05.014","article-title":"Cost-effective bioprocess design for the manufacture of allogeneic CAR-T cell therapies using a decisional tool with multi-attribute decision-making analysis","volume":"137","author":"Jenkins","year":"2018","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.ymthe.2024.11.035_bib158","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.tibtech.2023.04.006","article-title":"Manufacturing innovation to drive down cell therapy costs","volume":"41","author":"Khang","year":"2023","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib159","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.11.035_bib160","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jconrel.2022.11.038","article-title":"Polymer- and lipid-based gene delivery technology for CAR T cell therapy","volume":"353","author":"Pinto","year":"2023","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2024.11.035_bib161","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri2000","article-title":"Graft-versus-host disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100792","article-title":"Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions","volume":"48","author":"Martinez-Cibrian","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.ymthe.2024.11.035_bib163","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2567.2009.03208.x","article-title":"The extensive polymorphism of KIR genes","volume":"129","author":"Middleton","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2024.11.035_bib164","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.01.002","article-title":"MICA polymorphism: biology and importance in immunity and disease","volume":"16","author":"Choy","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymthe.2024.11.035_bib165","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.ymthe.2021.06.022","article-title":"Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection","volume":"29","author":"Peraro","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.035_bib166","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s42003-021-02237-4","article-title":"Immunological considerations and challenges for regenerative cellular therapies","volume":"4","author":"Petrus-Reurer","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymthe.2024.11.035_bib167","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MOT.0000000000000041","article-title":"Innate immune cells in transplantation","volume":"19","author":"Spahn","year":"2014","journal-title":"Curr. Opin. Organ Transpl."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624007627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624007627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:14:25Z","timestamp":1759612465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624007627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":167,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525001624007627"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.035","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing allorejection in off-the-shelf CAR-engineered cell therapies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}